All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Nada Hamad, St Vincent's Hospital, Sydney, AU and Silvy Lachance, Maisonneuve-Rosemont Hospital, Montreal, CA. We asked, How can patient-reported QoL change our view on unmet needs in GvHD?
How can patient-reported QoL change our view on unmet needs in GvHD?
The main topic of this podcast revolves around documenting the quality of life (QoL) of patients with acute and chronic GvHD. Lachance focused her part of the talk on patient-reported outcomes regarding the impact GvHD has on aspects of their daily life. Research demonstrated that GvHD severity, long term corticoid treatment or being corticoid resistant have a significant impact on QoL.
Hamad continues the conversation by exploring the stress of survival for patients undergoing bone marrow transplantation. She believes that patient self-reported symptoms should direct future research on GvHD treatment and prevention.
Subscribe to get the best content related to GvHD delivered to your inbox